ABT-863 / Abilita Therapeutics - LARVOL DELTA

ABT-863: The next generation anti-CCR8 immuno-oncology antibody therapeutic (AACR 2025) - "Because of its distinct pharmacology, this mechanism may offer more robust modulation of the TME and immune responses, potentially enhancing therapeutic efficacy, while avoiding unnecessary safety risks of depleting Tregs in healthy tissues or other CCR8-expressing cell types. In conclusion, ABT-863 is a differentiated first-in-class inverse agonist antibody with the potential to provide superior efficacy, improved safety and more favorable patient outcomes."

Immuno-oncology • IO biomarker • Colon Cancer • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • CCR8

ABT-863 is a first-in-class inverse agonistic anti-CCR8 antibody that blocks suppressive Treg activity without cell depletion to more safely promote an anti-tumor immune response (SITC 2025) - "Cytokine and chemokine blood analysis demonstrated elevated circulating levels of IL-10, previously linked to reinvigoration of exhausted CD8+ T cells and enhanced anti-tumor immunity.Conclusions ABT-863 is a first-in-class CCR8 inverse agonist antibody that promotes the anti-tumor response, modulating Treg suppressive activity, without cell depletion, offering a novel and potentially safer MoA. ABT-863 could represent a transformative immunotherapy approach targeting CCR8+ Tregs in solid tumors by coupling its robust anti-tumor activity, and its synergy with PD-1 blockade, with the potential differentiation for a better safety profile and a broader therapeutic window compared to other clinical candidates.Ethics Approval The animal studies have been conducted with a CRO, and have been approved by their internal IACUC."

Colon Cancer • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • CCR8 • CD8 • IL10